Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

buflomedil

Known as: 2,4,6-trimethoxyphenyl-3-pyrrolidine propyl ketone, blufomedil, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Hypothenar hammer syndrome (HHS) is an uncommon form of secondary Raynaud phenomenon, occurring mainly in subjects who use the… 
2006
2006
BACKGROUND Nicotine reduces skin-flap survival. Pharmacologic therapy may represent an alternative treatment strategy to… 
Highly Cited
2005
Highly Cited
2005
Background:Recurrent complex regional pain syndrome I is not rare in the pediatric population. The authors conducted this study… 
Highly Cited
2001
Highly Cited
2001
The aim of this work was to study the release mechanisms of drugs having different solubility (buflomedil pyridoxalphosphate 65… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1995
Highly Cited
1995
Swellable controlled release devices of buflomedil pyridoxalphosphate in hydroxypropyl methylcellulose were prepared, and their… 
1991
1991
The effect of buflomedil to protect skin tissue from ischemia and necrosis was studied in random cutaneous flaps. Measurements… 
Review
1987
Review
1987
Pentoxifylline (oxpentifylline) is an orally active haemorheological agent for the treatment of peripheral vascular disease… 
  • figure 1
  • figure 2
  • figure 3
  • table I
  • table II
1984
1984
In a double-blind, randomised multicentre study buflomedil, a vasoactive substance, was compared with placebo in the treatment of… 
  • table I
  • table IV
1981
1981
This brief communication outlines re cent experiments on the effects of buflo medil, a new vasoactive agent, on red cell… 
  • table 1
  • table 2
Review
1981
Review
1981
A brief review of the pharmacology, pharmacokinetics, and metabolism of buf lomedil-HCl is presented providing a phar macologic… 
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4